Previous Article | Next Article ![]()
Journal of Virology, May 2004, p. 4866-4875, Vol. 78, No. 9
0022-538X/04/$08.00+0 DOI: 10.1128/JVI.78.9.4866-4875.2004
Copyright © 2004, American Society for Microbiology. All Rights Reserved.
Department of Biology, Emory University, Atlanta, Georgia 30322,1 Departments of Medicine and of Microbiology and Immunology, Emory University School of Medicine and the Emory Vaccine Center, Atlanta, Georgia 303292
Received 17 July 2003/ Accepted 9 December 2003
|
|
|---|
|
|
|---|
![]() View larger version (20K): [in a new window] |
FIG. 1. Schematic of viremia (bold line), target cell (dashed line), and virus-specific CD8+-T-cell counts (dashed-dotted line) in primary HIV infection.
|
Here, we sought to resolve the roles of target cell limitation and virus-specific immune responses in the control of early viral replication by analyzing primary SIVmac239 infection in rhesus macaques (Macacca mulatta), one of the most commonly used animal models for studies of AIDS pathogenesis (6). The advantages of an animal model for our purposes are the abilities to control for the timing of infection and to frequently monitor the virus load and the levels of target cells and virus-specific immune responses. In the experiment we analyze (8a), we interfered with the natural course of primary SIV infection in half of the animals by inhibiting the costimulatory signals T cells require to become activated by antigen-presenting cells and to initiate the differentiation of antigen-presenting cells and B cells. As a consequence, the treated animals have impaired SIV-specific CD8+-T-cell responses and delayed SIV-specific antibody responses. The resulting variance in the levels of SIV-specific immunity allowed us to investigate the determinants of primary SIV replication.
The modeling approach we pursued was to fit two simple models to the viremia measurements of the animals, one that describes the interaction between the virus and its target cells only and an extended model which additionally takes into account the inhibitory effect of virus-specific immune responses on viral replication. Measurements of the levels of target cells and virus-specific CD8+ T cells were incorporated into the model as components of the viral growth rate. Comparing the goodness of fit of the two models, we can determine whether the virus-specific CD8+-T-cell response plays a significant role in primary infection.
|
|
|---|
Figure 2 shows the measurements relevant for our study: the viremia, the density of proliferating CD4+ T cells (which constitute the most important target cells for virus replication), the density of proliferating CD8+ T cells (a potential surrogate marker for the SIV-specific CD8+-T-cell response during primary infection), and the sum of the densities of SIV Gag181-189- and SIV Tat23-35-specific CD8+ T cells in peripheral blood. Figure 2 gives important insights into the relationship between viral replication and the levels of target cells and virus-specific CD8+-T-cell responses. While in the treated animals Ki67+ CD4+ T cells decrease during the first 10 days of infection and remain low thereafter, they only temporarily attain low levels in the untreated animals. Furthermore, the virus-specific CD8+-T-cell response in the treated animals is weaker than in the untreated animals. As a consequence of these differences in the levels of target cells and virus-specific CD8+-T-cell responses, treated and untreated groups differ in their viremia. The peak viremia is significantly lower in the treated group than in the untreated group, while the postpeak viremia is significantly higher (8a). Intuitively, the higher peak viremia in the untreated animals could be attributed to higher target cell levels, and the lower postpeak viremia in the untreated group could be explained by the stronger virus-specific CD8+-T-cell responses. To quantitatively assess the competing effects of target cells and virus-specific CD8+ T cells on viral replication, we analyzed these data by using population dynamic models.
![]() View larger version (29K): [in a new window] |
FIG. 2. Measurements of viremia (a), Ki67+ CD4+ T cells (b), Ki67+ CD8+ T cells (c), and the sum of Gag181-189- and Tat28-35-specific CD8+ T cells (d) in treated and untreated animals. The period during which the costimulatory blocker was applied is shaded.
|
A common approach to investigate the roles of target cell limitation and virus-specific CD8+-T-cell responses in primary infection would be to construct a dynamic model describing the three populations in questionvirus, target cells, virus-specific CD8+ T cellsand their interaction (Fig. 3a). The disadvantage of this approach is that one has to deal with a fairly large number of growth, death, and interaction terms, each associated with its own parameters. For the simplest model describing the interaction between the virus, its target cells, and the virus-specific CD8+ T cells, one has to deal with at least nine parameters (Fig. 3a offers a sample model). Furthermore, many interaction mechanisms,such as the depletion of CD4+ T cells or the stimulation of CD8+ T cells by the virus, are not well understood and their mathematical formulation will therefore be inherently speculative.
![]() View larger version (15K): [in a new window] |
FIG. 3. Diagrammatic comparison between the common approach (a) and our alternative approach (b). The common approach takes into account many aspects of the interaction between the virus, its target cells (mainly CD4+ T cells), and virus-specific CD8+-T-cell responses and therefore involves many (unknown) interaction mechanisms and parameters. Our alternative approach focuses on the effect of the target cells and virus-specific CD8+ T cells on virus replication and ignores all other aspects of the interaction, thus requiring many fewer parameters. The equations of population dynamic models that can be used for either approach are shown in order to illustrate the differences between the common approach and our alternative approach. The model of the common approach has four variables that denote the densities of susceptible and productively infected CD4+ T cells (T and T*, respectively) free virus (V), and virus-specific CD8+ T cells (E). The dot above the variables denotes the derivative with respect to time. This model assumes that susceptible CD4+ T cells are produced at a constant rate , die at a rate dT, and are infected by free virus at a rate ßTV. Productively infected CD4+ T cells are assumed to die at the rate of T and are cleared by virus-specific CD8+ T cells at a rate of kT*E. Free virus is produced by productively infected CD4+ T cells at a rate of T* and is cleared at the rate of cV. Finally, virus-specific CD8+ T cells are assumed to arise at a rate E and to die at a rate E. The model used in the alternative approach has only one variable for free virus V. The growth rate g of the virus is a function of the density of susceptible CD4+ T cells (T) and the density of virus-specific CD8+ T cells (E). For the specific functions we assume for the viral growth rate g, see Appendix.
|
We constructed two models (see Appendix), one which describes the interaction between the virus and its target cells only (which we refer to as the target cell-based model) and an extended version of the target cell-based model, which additionally takes into consideration the potential effect of CD8+-T-cell responses (which we refer to as the immune control model). We fit the models to the virus load measurements between day 0 and day 28 after infectiona time interval which coincides with the period of treatment and is, therefore, convenient to define the period of primary infection. However, our results do not depend on this particular time interval. Comparing the fits of these two models using an F test (see Appendix) allows us to determine whether virus-specific CD8+ T cells play a significant role in controlling virus replication in primary infection.
In the immune control model, we need to incorporate measures of the virus-specific CD8+-T-cell response. Our data set contains two alternative measurements: (i) Gag181-189- and Tat23-35-specific CD8+ T cells and (ii) proliferating CD8+ T cells (as measured by the expression of the nuclear antigen Ki67). We prefer proliferating CD8+ T cells over Gag181-189- and Tat23-35-specific CD8+ T cells for several reasons. First, we do not know to what extent the Gag181-189- and Tat23-35-specific CD8+ T cells reflect the total extent of the CD8+-T-cell response in each animal. Although matched for Mamu A*01, these outbred animals differ at known major histocompatibility complex class I alleles as well as at potentially undefined major histocompatibility complex class I alleles (8a). Therefore, the extent to which the Gag181-189- and Tat23-35-specific CD8+ T cells reflect the total extent of the CD8+-T-cell response may differ from animal to animal. Moreover, we have evidence for immunologic escape from virus-specific CD8+-T-cell responses directed against the Tat23-35 epitope in all animals by day 20, and thus the Tat23-35-specific CD8+-T-cell response may no longer affect the prevailing virus population after this time point (8a). Here, we therefore present results based on proliferating CD8+ T cells. We emphasize, however, that a parallel analysis based on Gag181-189- and Tat23-35-specific CD8+ T cells yields similar results (see Appendix).
We tested our model selection scheme by first applying it to the treated group. Due to the fact that the treated group had severely impaired specific immune responses to the virus, the contribution of CD8+-T-cell responses to viral replication should be negligible, i.e., the immune control model is not expected to fit significantly better than the target cell-based model.
|
|
|---|
![]() View larger version (17K): [in a new window] |
FIG. 4. Fitting the target cell-based model (dashed lines) and the immune control model (solid lines) to the virus load of the treated animals. Only for animal REo6 does the immune control model fit significantly better.
|
|
View this table: [in a new window] |
TABLE 2. Parameter estimates for the fits with the immune control modela
|
![]() View larger version (19K): [in a new window] |
FIG. 5. Fitting the target cell-based model (dashed lines) and the immune control model (solid lines) to the virus load of the untreated animals. The immune control model fits significantly better for all animals.
|
![]() View larger version (20K): [in a new window] |
FIG. A1. Comparison of the fits of the immune control model, based on different measures of SIV-specific CD8+-T-cell responses, in the treated animals (a) and in the untreated animals (b). Fits of the immune control model based on the sum of the Gag181-189- and Tat23-35-specific CD8+ T cells are shown as solid red lines, and fits of the immune control model based on Ki67+ CD8+ T cells are shown as solid black lines. Fits of the target cell-based model are shown as dashed lines.
|
|
View this table: [in a new window] |
TABLE 1. Parameter estimates for the fits with the target cell-based modela
|
No impact of resting CD4+ T cells on viral replication. To test for the relevance of viral replication in resting CD4+ T cells (as defined by CD4+ T cells that do not express Ki67) in primary infection, we constructed extensions of the target cell-based model and the immune control model that take into account the potential for viral replication in resting CD4+ T cells (see Appendix). We found that the inclusion of replication in resting CD4+ T cells did not explain early viral replication better than the target cell-based model or the immune control model (data not shown). Thus, even though the infection of resting cells is reported (9), according to our analysis, the contribution of the compartment of resting CD4+ T cells to viral replication is negligible. Furthermore, an extension of our analysis shows that a significant impact of antibody responses on viral containment in primary infection can also be ruled out (data not shown). This finding is consistent with low levels of antibodies in the treated animals and undetectable levels in the untreated animals during primary infection (8a).
|
|
|---|
Our study goes beyond CD8-depletion experiments and earlier quantitative studies in that we have carefully taken into account the impact of target cells on viral replication. The CD8-depletion study during primary SIV infection by Schmitz et al. (26), for example, did not measure the levels of proliferating CD4+ T cells. This omission makes solid conclusions about the role of target cell limitation and virus-specific CD8+ T-cell responses difficult. Similarly, the study by Stafford et al. (27), in which mathematical models were fitted to data on primary viremia in HIV-infected patients, did not take into consideration any measurements of target cells.
Our study, which used an approach very different from CD8-depletion models, largely agrees with the conclusions of Schmitz et al. (26) that virus-specific CD8+ T cells play a crucial role in primary SIV infection. However, our conclusions with regard to how early viral replication is controlled at its peak differ from those of Schmitz et al. (26). Schmitz et al. (26) find that the depletion of CD8+ cells affects neither the timing of the peak nor the peak level of viremia and, thus, rule out a role of the virus-specific CD8+-T-cell responses in the containment of viral replication at its peak. From our analysis, on the other hand, we conclude that viral containment at the peak is not due to target cell limitation.
Our finding that neither viral containment at the peak nor postpeak control of viral replication can be explained by target cell limitation in the untreated animals also disagrees with the conclusions of Stafford et al. (27) that target cell limitation could account for the pattern of viral replication during the first 100 days of infection. This discrepancy is due to the fact that the model employed by Stafford et al. (27) predicts that the levels of target cells decrease during primary infection, while we observed no such decrease in the untreated animals.
Our analysis is unable to identify the factors that control viral replication at its peak in the untreated group. We ruled out the possibility that containment of viral replication at its peak is due to target cell limitation in this group. Moreover, virus-specific CD8+-T-cell responses seem unlikely to be responsible for controlling SIV replication at the peak because they come up after the peak of the viremia. Thus, alternative factors may have to be invoked. It is possible, for example, that innate immune responses play a significant role in the control viral replication at its peak, which has been found to be the case in lymphocytic choriomeningitis virus infection in mice (3).
Even though we can show that virus-specific CD8+ T cells play a significant role in the control of primary infection, the prediction of the immune control model still deviates from the virus load observed. Several factors could account for the deviation. First, the measurements of target cells and virus-specific cellular immune responses in the blood of the animals may not reflect the levels of these cells in the entire animal. In particular, the redistribution of cells may confound our ability to predict viral replication. Second, our assumption that all proliferating CD4+ T cells are equally susceptible to infection may be overly simplistic. Should a subset of the proliferating CD4+ T cells, as for example SIV-specific T helper cells, be significantly more susceptible and productive than proliferating CD4+ T cells on average, our target cell-based model would have to be revised. Although there is evidence for increased susceptibility of HIV-specific CD4+ T cells during HIV infection (7), our target cell-based model would be inadequate only if specific CD4+ T cells were also shown to be substantially more productive than non-SIV-specific, proliferating CD4+ T cells. Third, the measured proliferating CD8+ T cells and Gag181-189- and Tat23-35-specific CD8+ T cells may not reflect the total extent of the overall cellular immune response. Last, immune responses other than cytotoxic T cells or antibodies, such as cytokines and chemokines released by T helper cells, may be at work. Since we did not measure cytokine or chemokine production in our experiments, we could not test for its impact on viral replication. In the future, experiments measuring levels of cytokines, chemokines, and virus-specific CD4+-T-cell responses combined with a quantitative analysis as presented here could address the detailed mechanisms of viral containment by the various branches of the immune system.
In the present analysis, we focused on primary infection and did not analyze the entire course of infection. A detailed analysis of all available data suggests that, especially during the later stages of infection, viral replication is determined by many factors, including antibodies and potentially unmeasured CD4+-T-cell-mediated responses (8a). Due to fully developed antibody responses and evident CTL escape in all the untreated animals after primary infection, our analysis is unlikely to yield the same straightforward results if applied to later stages of infection.
Given all of the caveats associated with the measurements on which we based our analysis and the limitation in our understanding of the dynamics of primary SIV infection in general, it is remarkable how well our extremely simple model accounts for the observed pattern of primary SIV replication. The insights into primary SIV infection gained from our study illustrate the power of mathematical models as tools for understanding the dynamics of viral infections.
|
|
|---|
![]() | (1) |
We assume that proliferating CD4+ T cells constitute the main target cells of the virus. The function T(t) is constructed by interpolating the measurements of the density of Ki67+ CD4+ T cells in blood by a smooth function (a cubic spline).
The above differential equation can be solved analytically:
![]() | (2) |
We fit the above expression to the logarithm of the observed virus load of each individual animal by separately minimizing the sum of squares of the residuals. This model (as all subsequent models) were fitted using the "optim()" routine of the R language of statistical computing (13) which allows us to confine the parameters to positive values. Bootstrap analysis was used to calculate 68% confidence intervals (CI) (8).
Immune control model.
To take into account the potential inhibition of viral replication by specific CD8+ T cells, we extend the target cell-based model (equation 1) by the additional term kE(t):
![]() | (3) |
As with the target cell-based model (equation 1), the immune control model can be solved analytically:
![]() | (4) |
Model comparison.
We use the target cell-based model (equation 1) and the immune control model (equation 3) to determine whether the immune response plays a significant role in controlling the primary infection. We adopt a standard statistical strategy: first, we fit the two models by minimizing the residual sum of squares; then we determine whether the additional parameter in the immune control model (equation 3) (which measures the contribution of the CD8+-T-cell responses) explains a significant fraction of the variation in the viremia that is not explained by the target cell-based model (equation 1). Formally, we can test for the significance of "betterness" of the fit with the immune control model (equation 3) by performing an F test on the residual sum of squares normalized by the appropriate degrees of freedom:
![]() | (5) |
= 0.05, then the virus-specific CD8+-T-cell response significantly contributes to the replication pattern of the virus in the primary infection.
Resting cell model.
To investigate the role of resting CD4+ T cells in viral replication, we extended the immune control model (equation 3) by the term r'R(t):
![]() | (6) |
Analysis based on Gag181-189- and Tat28-35-specific CD8+ T cells. The analysis presented in the main text is based on proliferating CD8+ T cells as a surrogate for the SIV-specific CD8+-T-cell response. Here, we present the results of an analysis based on the measurements of Gag181-189- and Tat23-35-specific CD8+ T cells. This alternative choice of a surrogate for the SIV-specific CD8+-T-cell responses affects only the fit of the immune control model and not the fit of the target cell-based model.
Figure A1a shows the fits of the immune control model based on the sum of Gag181-189- and Tat23-35-specific CD8+ T cells (solid red lines) to the treated animals. The fits based on the sum of Gag181-189- and Tat23-35-specific CD8+ T cells are very similar to the fits based on Ki67+ CD8+ T cells (solid black lines). Based on either of the two measurements of virus-specific CD8+-T-cell responses, the immune control model does not explain the pattern of viral replication significantly better than the target cell-based model (dashed lines) in three out of four animals (Tables 2 and A1).
Figure A1b shows the fits of the immune control model based on the sum of Gag181-189- and Tat23-35-specific CD8+ T cells (solid red lines) to the untreated animals and compares them with the fits based on Ki67+ CD8+ T cells (solid black lines). Except for animal RBm6, the fits of the immune control model based on the sum of the Gag181-189- and Tat23-35-specific CD8+ T cells are very similar to the fits of the same model based on Ki67+ CD8+ T cells.
Table A1 shows the parameter estimates of the immune control model based on the sum of Gag181-189- and Tat23-35-specific CD8+ T cells and compares the fit of the immune control model to the fit of the target cell-based model. In three out of four animals, the immune control model explains the pattern of viral replication significantly better than the target cell-based model. As in the analysis based on Ki67+ CD8+ T cells, the intrinsic death rate of infected cells, a', is estimated as zero in all untreated animals, suggesting that, in primary infection, infected cells are killed mainly by CTL.
|
View this table: [in a new window] |
TABLE A1. Parameter estimates for the fits with the immune control model based on the sum of Gag181-189- and Tat28-35-specific CD8+ T cellsa
|
We gratefully acknowledge the support of the Deutsche Forschungsgemeinschaft grant Re 1618/2-1 (R.R.R.) and the National Institutes of Health grants AI 49334 (R.A. and R.R.R.) and RO1 AI49155 (M.B.F. and S.I.S.). Mark Feinberg is an Elizabeth Glaser Scientist of the Pediatric AIDS Foundation.
|
|
|---|
This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Copyright © 2009 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»